Whole Foods Market (NASDAQ:WFM): After meeting with Whole Foods’s CEO, Wells Fargo is more confident that the company is moving further ahead of its competition, driven by retail-digital innovation, localization, quality standards, and better value. The firm reports that the company’s new stores are exceeding expectations, and it keeps an Outperform rating on the stock.
Valspar (NYSE:VAL): Deutsche Bank upgraded Valspar to Buy from Hold, citing valuation and expectations for strong growth in 2014. The firm raised its price target for shares to $75 from $72.
Sarepta Therapeutics (NASDAQ:SRPT): After Sarepta presented 96-week follow-up data from a study of eteplirsen, Piper Jaffray said that its still sees the company as on track to file a new drug application for the drug in the first half of next year. Piper keeps its Overweight rating and $58 target on Sarepta shares.
Endo Health Solutions (NASDAQ:ENDP): After Endo Health’s stock dropped due to large share gains for the generic version of the company’s Lidoderm, Buckingham still expects the potential for accretive acquisitions to lift the company’s earnings per share and the stock’s multiple. The firm also notes that Endo receives royalties on the generic version of Lidoderm from the maker of the generic drug, Actavis. Buckingham keeps a Buy rating on Endo.
Investing Insights: Can United Technologies Continue Its Move to All Time Highs?